Commercial newswire·KR·
Flen Health, 차세대 상처 치료제용 재조합 효소 생산 위해 AGC Biologics 선정
AGC Biologics 하이델베르크 시설, 임상 2상 위한 락토페록시다아제·글루코스 산화효소 GMP 개발 주도 AGC Biologics 하이델베르크 시설, 임상 2상 위한 락토페록시다아제·글루코스 산화효소 GMP 개발 주도
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Form 8.3 - GAMMA COMMUNICATIONS PLC
- Africa Meal Kit Market Outlook 2026-2032 | Urbanization, Convenience and Demand for Home-Cooked Meals Drive New Opportunities
- Global Horse Racing Market 2026-2031: Digital Wagering, Live Streaming and Sponsorship Opportunities Drive Growth
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →Shared via PPN World — real-time press release intelligence.